You are here:
Novartis
#

Novartis

Get Alerts

Articles

View all

To the brink and back: Key business events in 2013

Dec 31, 2013

To the brink and back: Key business events in 2013

The RBI starting the year off with rate cuts and then reversing its stance on concerns about widening current account deficit. Fears that the US Federal Reserve will start cutting its bond purchase programme sooner than expected only added to the worries. Foreign funds pulled out of the Indian equities and debt in hoards. #Infosys #Inflation #Gold #P. Chidambaram #RBI #Rupee #Ben Bernanke #Phaneesh Murthy #Narayana Murthy #WPI #US Federal Reserve #Raghuram Rajan #Tesco #Ambani #Pepsi #iGate #CPI #CAD #Jignesh Shah #Novartis #NSEL #taper #Tata Trent #RearView2013
Pharma sector registers single digit growth in 2013; regulators increase scrutiny

Dec 29, 2013

Pharma sector registers single digit growth in 2013; regulators increase scrutiny

The Indian pharma sector, estimated to be around Rs 1.5 lakh crore, recorded single digit growth for the first time in several years on account of deeper price cuts under pricing policy and selective boycott of companies by the retailers. #FDI #Cipla #Sun Pharmaceuticals #Wockhardt #Ranbaxy #Pharma #Torrent Pharmaceuticals #WTO #Biocon #gsk #Pfizer #Piramal Enterprises #USFDA #Novartis #Dr. Reddy #RearView2013 #Elder #IPAB #Zydus #Cadilla
EU fines Ranbaxy, 8 others for blocking cheaper drugs

Jun 20, 2013

EU fines Ranbaxy, 8 others for blocking cheaper drugs

The punishments follow a 2009 report by the European Commission on the pharmaceutical sector, which said "pay-for-delay" deals lead to consumers paying as much as 20 percent more for their medicines. #BreakingNow #Drugs #EU #Ranbaxy #Healthcare #Novartis
Cancer immunotherapy drugs will soon be a $35 bn global industry

May 22, 2013

Cancer immunotherapy drugs will soon be a $35 bn global industry

A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with potential sales of $35 billion a year. #Business #ThisisNext #science #Health #Citigroup #Cancer #GlaxoSmithKline #Merck & Co. #AstraZeneca #Novartis #Sector Spotlight #Immunotherapy drugs #Amgen
Novartis patent row: US 'concerned' over India's patent norms, innovation

May 02, 2013

Novartis patent row: US 'concerned' over India's patent norms, innovation

Raising questions over innovation climate in India, the US has said the recent decision by India's Supreme Court to prohibit patent of Novartis' cancer drug Glivec could "preclude issuance of a patent" in the country. #India #WhyNow #Drugs #Innovation #Patent #Pharma #Novartis #glivec

BLOG POSTS

View all

Why a global fight against cancer is a good idea

Apr 10, 2013

Why a global fight against cancer is a good idea

In a substantive paper published today in the journal Nature Reviews, a group of authors from Singapore, the USA and Brazil evaluate the cost of cancer medication in low and middle income countries. #WhyNow #Cancer #Healthcare #Diabetes #Novartis #glivec #Merck #Dabur Pharma

Wire

View all

Why a global fight against cancer is a good idea

Sep 11, 2014

Japanese Research Scandal Involving Novartis Blood Pressure Drug Widens

The Japanese scandal over research using the Novartis blockbuster hypertension drug Diovan (valsartan) continues to widen. The first major figure brought down in the scandal was Hiroaki Matsubara, a prominent cardiologist and researcher at Kyoto Pref...
Why a global fight against cancer is a good idea

Aug 30, 2014

Study: New Heart Failure Drug Shows Big Promise

A new study reports one of the biggest potential advances against heart failure in more than a decade — a first-of-a-kind, experimental drug that lowered the chances of death or hospitalization by about 20 percent. Doctors say the Novartis drug — whi... #Europe #American Heart Association #Novartis #UT Southwestern Medical Center #Dallas, Texas #Northwestern University #New England Journal of Medicine